{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:42:29Z","timestamp":1786372949920,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["UO1 DK066143"],"award-info":[{"award-number":["UO1 DK066143"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["U01 DK066174"],"award-info":[{"award-number":["U01 DK066174"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["U24 DK137522"],"award-info":[{"award-number":["U24 DK137522"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["U24 DK066116"],"award-info":[{"award-number":["U24 DK066116"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>In a large longitudinal study of predialysis CKD, plasma fibroblast growth factor 23 was stable in most of the children when modeled as linear trajectories over time<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Children with rapidly rising fibroblast growth factor 23 trajectories exhibited lower eGFR, higher serum phosphorus, proteinuria, and anemia compared with those with stable levels<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Longitudinal fibroblast growth factor 23 monitoring provides a powerful, independent predictor of kidney disease progression in children with CKD<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In children and adults, plasma fibroblast growth factor 23 (FGF23) concentrations increase early in CKD and associate with disease progression and adverse cardiovascular outcomes. However, longitudinal changes in FGF23 in children with progressive CKD are not well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We measured\n                      <jats:italic toggle=\"yes\">c<\/jats:italic>\n                      -terminal FGF23 biannually and eGFR in 543 children with CKD stages 2\u20134 enrolled in the CKD in children study. All participants had 2-3 FGF23 measurements. We used a linear mixed model to estimate the average percent change in FGF23 and eGFR over time for the overall cohort and latent group-based trajectory modeling to identify populations with distinct patterns of change in FGF23 concentration, eGFR, and phosphorus\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -score. We used Cox proportional hazards model to examine the risk of progression to kidney failure according to FGF23 trajectory group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At study enrollment, the median age was 12 years and eGFR 52 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . In univariate models with repeated measures, FGF23 increased by a mean of 3.7% annually, and eGFR decreased by 3.8% annually over a median observation period of 4 years. We identified three distinct FGF23 trajectories: stable in 64% of participants (FGF23 slope 0% per year); slowly rising in 30% (slope 6% per year) and rapidly rising in 6% (slope 39% per year). Membership in the faster-rising trajectory groups was associated with lower eGFR, higher serum phosphorus, greater proteinuria, and anemia. With subsequent median 4.9 years of follow-up, the risk of kidney failure was 1.7-fold higher (95% confidence interval, 1.09 to 2.67) in the slowly rising and 8-fold higher (95% confidence interval, 2.41 to 23.56) in the rapidly rising FGF23 trajectory group compared with the stable trajectory group, in fully adjusted analyses. Phosphorus\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      -score trajectories did not associate with progression to kidney failure in adjusted models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>By characterizing longitudinal changes in FGF23 in children with CKD, we find that FGF23 was stable in most children. Membership in the faster-rising FGF23 trajectory groups associates with increased risk of progression to kidney failure. Future studies are needed to investigate whether FGF23 is a modifiable cause or a consequence of CKD progression in children with CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000000954","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:02:48Z","timestamp":1770310968000},"page":"567-577","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Fibroblast Growth Factor 23 Trajectories in Children and Association with CKD Progression"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-0127","authenticated-orcid":false,"given":"Farzana","family":"Perwad","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Matheson","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2944-998X","authenticated-orcid":false,"given":"Eva","family":"Glenn Lecea","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-2367","authenticated-orcid":false,"given":"Tamara","family":"Isakova","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8052-416X","authenticated-orcid":false,"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-0515","authenticated-orcid":false,"given":"Harald","family":"J\u00fcppner","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-1442","authenticated-orcid":false,"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Warady","sequence":"additional","affiliation":[{"name":"Children's Mercy Kansas City, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-5242","authenticated-orcid":false,"given":"Susan","family":"Furth","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-5101","authenticated-orcid":false,"given":"Derek K.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2054-6898","authenticated-orcid":false,"given":"Anthony A.","family":"Portale","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"For the CKiD Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"3","key":"B1-20260417","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00467-019-04458-6","article-title":"The CKiD study: overview and summary of findings related to kidney disease progression","volume":"36","author":"Atkinson","year":"2021","journal-title":"Pediatr Nephrol."},{"issue":"4","key":"B2-20260417","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamacardio.2019.0375","article-title":"Risk of cardiovascular disease and mortality in young adults with end-stage renal disease: an analysis of the US renal data system","volume":"4","author":"Modi","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"11","key":"B3-20260417","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2215\/CJN.02110216","article-title":"Fibroblast growth factor 23 and risk of CKD progression in children","volume":"11","author":"Portale","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B4-20260417","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"10","key":"B5-20260417","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/ki.2010.313","article-title":"Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease","volume":"78","author":"Hasegawa","year":"2010","journal-title":"Kidney Int."},{"issue":"12","key":"B6-20260417","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"issue":"1","key":"B7-20260417","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2215\/CJN.02110217","article-title":"FGF23 and left ventricular hypertrophy in children with CKD","volume":"13","author":"Mitsnefes","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B8-20260417","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1681\/ASN.2017070772","article-title":"Longitudinal FGF23 trajectories and mortality in patients with CKD","volume":"29","author":"Isakova","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B9-20260417","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest."},{"issue":"6","key":"B10-20260417","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med."},{"issue":"1","key":"B11-20260417","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int."},{"issue":"4","key":"B12-20260417","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MNH.0000000000000514","article-title":"Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease","volume":"28","author":"Babitt","year":"2019","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"5","key":"B13-20260417","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2215\/CJN.01941205","article-title":"Design and methods of the chronic kidney disease in children (CKiD) prospective cohort study","volume":"1","author":"Furth","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B14-20260417","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2215\/CJN.05840513","article-title":"Disordered FGF23 and mineral metabolism in children with CKD","volume":"9","author":"Portale","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7","key":"B15-20260417","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00467-011-1870-5","article-title":"Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease","volume":"26","author":"Siomou","year":"2011","journal-title":"Pediatr Nephrol."},{"issue":"4","key":"B16-20260417","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","article-title":"Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease","volume":"99","author":"Pierce","year":"2021","journal-title":"Kidney Int."},{"issue":"3","key":"B17-20260417","doi-asserted-by":"crossref","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical practice guideline for screening and management of high blood pressure in children and adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics."},{"issue":"5","key":"B18-20260417","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","article-title":"Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children","volume":"58","author":"Colantonio","year":"2012","journal-title":"Clin Chem."},{"key":"B19-20260417","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2147\/CLEP.S265287","article-title":"Trajectory modelling techniques useful to epidemiological research: a comparative narrative review of approaches","volume":"12","author":"Nguena Nguefack","year":"2020","journal-title":"Clin Epidemiol."},{"key":"B20-20260417","doi-asserted-by":"crossref","first-page":"106311","DOI":"10.1016\/j.neubiorev.2025.106311","article-title":"Precision medicine in substance use disorders: integrating behavioral, environmental, and biological insights","volume":"176","author":"Guerrin","year":"2025","journal-title":"Neurosci Biobehav Rev."},{"issue":"1","key":"B21-20260417","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ndt\/gfs411","article-title":"Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease","volume":"28","author":"Wan","year":"2013","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"B22-20260417","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s10157-022-02238-5","article-title":"Factors associated with 1-year changes in serum fibroblast growth factor 23 levels in pediatric patients with chronic kidney disease","volume":"26","author":"Yamamura-Miyazaki","year":"2022","journal-title":"Clin Exp Nephrol."},{"issue":"1","key":"B23-20260417","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1681\/ASN.2012070713","article-title":"Mineral metabolites and CKD progression in African Americans","volume":"24","author":"Scialla","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B24-20260417","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1053\/j.ajkd.2019.09.009","article-title":"Serial fibroblast growth factor 23 measurements and risk of requirement for kidney replacement therapy: the CRIC (chronic Renal Insufficiency Cohort) study","volume":"75","author":"Mehta","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B25-20260417","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/ndt\/gft456","article-title":"Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease","volume":"29","author":"Bouma-de Krijger","year":"2014","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B26-20260417","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2215\/CJN.07480714","article-title":"Progression of pediatric CKD of nonglomerular origin in the CKiD cohort","volume":"10","author":"Fathallah-Shaykh","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B27-20260417","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1053\/j.ajkd.2015.01.008","article-title":"Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) cohort","volume":"65","author":"Warady","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B28-20260417","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.kint.2017.05.006","article-title":"Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease","volume":"92","author":"Harambat","year":"2017","journal-title":"Kidney Int."},{"issue":"6","key":"B29-20260417","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1053\/j.ajkd.2015.06.015","article-title":"Hyperuricemia and progression of CKD in children and adolescents: the chronic kidney disease in children (CKiD) cohort study","volume":"66","author":"Rodenbach","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B30-20260417","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.ajkd.2019.11.004","article-title":"Plasma soluble urokinase plasminogen activator receptor (suPAR) and CKD progression in children","volume":"76","author":"Weidemann","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B31-20260417","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1038\/s41598-020-59962-9","article-title":"Oxidant stress and renal function among children with chronic kidney disease: a repeated measures study","volume":"10","author":"Jacobson","year":"2020","journal-title":"Scientific Rep."},{"issue":"12","key":"B32-20260417","doi-asserted-by":"crossref","first-page":"e4875","DOI":"10.1210\/clinem\/dgaa665","article-title":"Intact and C-terminal FGF23 assays-do kidney function, inflammation, and low iron influence relationships with outcomes?","volume":"105","author":"Sharma","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"B33-20260417","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:40:07Z","timestamp":1786369207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000954"}},"subtitle":["The CKD in Children Study"],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000954","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"2025-08-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}